Cite
Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.
MLA
Li, Zhiguang, et al. “Genetic Variation in Targets of Lipid-Lowering Drugs and Amyotrophic Lateral Sclerosis Risk: A Mendelian Randomization Study.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, vol. 25, no. 1/2, Feb. 2024, pp. 197–206. EBSCOhost, https://doi.org/10.1080/21678421.2023.2255622.
APA
Li, Z., Tian, M., Jia, H., Li, X., Liu, Q., Zhou, X., Li, R., Dong, H., & Liu, Y. (2024). Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 25(1/2), 197–206. https://doi.org/10.1080/21678421.2023.2255622
Chicago
Li, Zhiguang, Mei Tian, Hongning Jia, Xin Li, Qi Liu, Xiaomeng Zhou, Rui Li, Hui Dong, and Yaling Liu. 2024. “Genetic Variation in Targets of Lipid-Lowering Drugs and Amyotrophic Lateral Sclerosis Risk: A Mendelian Randomization Study.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 25 (1/2): 197–206. doi:10.1080/21678421.2023.2255622.